{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:51:53Z","timestamp":1789685513304,"version":"4.0.1"},"reference-count":32,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunology Research"],"published-print":{"date-parts":[[2022,8,18]]},"abstract":"Biological targeted therapy serves as a new alternative treatment for psoriasis due to its minimal side effects. This study is aimed at examining the drug effectiveness and safety of risankizumab and ustekinumab for psoriasis treatment, so as to provide a reference for clinical decision-making. Databases from Embase, Web of Science, PubMed, and Cochrane Library were gathered, starting from inception to March 1, 2022, for randomized controlled trials regarding risankizumab and ustekinumab for psoriasis treatment. All retrieved articles were carefully selected in strict accordance with a set of inclusion and exclusion criteria. Stata 15.0 and RevMan 5.4 were applied to perform meta-analysis and risk of bias assessment. A total of two trials with three NCTs were selected, with 384 participants in the risankizumab group and 140 participants in ustekinumab. Meta-analysis showed that in the long-term and short-term PASI100, risankizumab was more effective than ustekinumab (\n \n RR<\/a:mtext>\n =<\/a:mo>\n 2.27<\/a:mn>\n <\/a:math>\n <\/jats:inline-formula>, 95% CI (1.77, 2.90), \n \n p<\/c:mi>\n <<\/c:mo>\n 0.05<\/c:mn>\n <\/c:math>\n <\/jats:inline-formula>; \n \n RR<\/e:mtext>\n =<\/e:mo>\n 2.33<\/e:mn>\n <\/e:math>\n <\/jats:inline-formula>, 95% CI (1.75, 3.08), \n \n p<\/g:mi>\n <<\/g:mo>\n 0.05<\/g:mn>\n <\/g:math>\n <\/jats:inline-formula>). In PASI90, \n \n RR<\/i:mtext>\n =<\/i:mo>\n 1.77<\/i:mn>\n <\/i:math>\n <\/jats:inline-formula>, 95% CI (1.54, 2.03), and \n \n p<\/k:mi>\n <<\/k:mo>\n 0.05<\/k:mn>\n <\/k:math>\n <\/jats:inline-formula> and \n \n RR<\/m:mtext>\n =<\/m:mo>\n 1.72<\/m:mn>\n <\/m:math>\n <\/jats:inline-formula>, 95% CI (1.48, 2.00), and \n \n p<\/o:mi>\n <<\/o:mo>\n 0.05<\/o:mn>\n <\/o:math>\n <\/jats:inline-formula>. In short-term PASI75, \n \n RR<\/q:mtext>\n =<\/q:mo>\n 1.23<\/q:mn>\n <\/q:math>\n <\/jats:inline-formula>, 95% CI (1.13, 1.34), and \n \n p<\/s:mi>\n <<\/s:mo>\n 0.05<\/s:mn>\n <\/s:math>\n <\/jats:inline-formula>. In sPGA of 0, the results at week-16 and week-52 showed that risankizumab was significantly more effective than ustekinumab (\n \n RR<\/u:mtext>\n =<\/u:mo>\n 2.24<\/u:mn>\n <\/u:math>\n <\/jats:inline-formula>, 95% CI (1.67, 3.01), \n \n p<\/w:mi>\n <<\/w:mo>\n 0.05<\/w:mn>\n <\/w:math>\n <\/jats:inline-formula>; \n \n RR<\/y:mtext>\n =<\/y:mo>\n 2.30<\/y:mn>\n <\/y:math>\n <\/jats:inline-formula>, 95% CI (1.80, 2.95), \n \n p<\/ab:mi>\n <<\/ab:mo>\n 0.05<\/ab:mn>\n <\/ab:math>\n <\/jats:inline-formula>). Risankizumab was significantly more effective than ustekinumab in improving the quality of life and PSS scores (\n \n RR<\/cb:mtext>\n =<\/cb:mo>\n 1.48<\/cb:mn>\n <\/cb:math>\n <\/jats:inline-formula>, 95% CI (1.26, 1.75), \n \n p<\/eb:mi>\n <<\/eb:mo>\n 0.05<\/eb:mn>\n <\/eb:math>\n <\/jats:inline-formula>; \n \n RR<\/gb:mtext>\n =<\/gb:mo>\n 2.01<\/gb:mn>\n <\/gb:math>\n <\/jats:inline-formula>, 95% CI (1.41, 2.85), \n \n p<\/ib:mi>\n <<\/ib:mo>\n 0.05<\/ib:mn>\n <\/ib:math>\n <\/jats:inline-formula>). Nevertheless, risankizumab and ustekinumab did not show significant difference in the incidence of adverse responses (\n \n RR<\/kb:mtext>\n =<\/kb:mo>\n 1.02<\/kb:mn>\n <\/kb:math>\n <\/jats:inline-formula>, 95% CI (0.75, 1.39), \n \n p<\/mb:mi>\n ><\/mb:mo>\n 0.05<\/mb:mn>\n <\/mb:math>\n <\/jats:inline-formula>). Risankizumab was more effective than ustekinumab for the treatment of psoriasis. The adverse reactions of both risankizumab and ustekinumab were similar and could be tolerated. Risankizumab might be a better alternative option for their treatment.<\/jats:p>","DOI":"10.1155\/2022\/2802892","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:05:49Z","timestamp":1660867549000},"page":"1-11","source":"Crossref","is-referenced-by-count":8,"title":["A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-2019","authenticated-orcid":true,"given":"Qianying","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-8988","authenticated-orcid":true,"given":"Xiaopei","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1872-4501","authenticated-orcid":true,"given":"Mingyi","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-241X","authenticated-orcid":true,"given":"Xiongfei","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-5905","authenticated-orcid":true,"given":"Jing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-0965","authenticated-orcid":true,"given":"Min","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-0908","authenticated-orcid":true,"given":"Qing","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8879-0857","authenticated-orcid":true,"given":"Mingling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075 Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.05.009"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.565"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.15577"},{"key":"7","article-title":"Treatment of psoriasis: before and now","volume":"114","author":"A. Osmancevic","year":"2017","journal-title":"L\u00e4kartidningen"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14949"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20595"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-018-0505-z"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/cpim.71"},{"key":"15","article-title":"A systematic review with meta-analysis of comparative efficacy and safety of risankizumab and ustekinumab for psoriasis treatment","author":"X. G. Qianying Yu"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2017.07.002"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0137-1"},{"issue":"5s","key":"22","first-page":"18","article-title":"Psoriasis risk factors and triggers","volume":"102","author":"E. B. Lee","year":"2018","journal-title":"Cutis"},{"issue":"1","key":"23","first-page":"97","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"F. Gr\u00e4n","year":"2020","journal-title":"The Yale Journal of Biology and Medicine"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2019.106657"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-017-2985-x"},{"issue":"1","key":"26","first-page":"64","article-title":"Dermatology life quality index in patients of psoriasis and its correlation with severity of disease","volume":"32","author":"J. M. Khan","year":"2020","journal-title":"Journal of Ayub Medical College, Abbottabad"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub4"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01902-w"},{"issue":"2","key":"29","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"X. Zhu","year":"2013","journal-title":"Journal of Drugs in Dermatology"},{"key":"30","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"F. Bai","year":"2019","journal-title":"Journal of Immunology Research"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"}],"container-title":["Journal of Immunology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2022\/2802892.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2022\/2802892.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2022\/2802892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:05:57Z","timestamp":1660867557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jir\/2022\/2802892\/"}},"subtitle":[],"editor":[{"given":"Fu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":32,"alternative-id":["2802892","2802892"],"URL":"https:\/\/doi.org\/10.1155\/2022\/2802892","relation":{},"ISSN":["2314-7156","2314-8861"],"issn-type":[{"value":"2314-7156","type":"electronic"},{"value":"2314-8861","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}